Rosa Pettinato

Rosa Pettinato

Auto-generated profile, based on publicly available information

Rosa Pettinato

Pediatrics and Medical Genetics, Oasi Research Institute - IRCCS, 94018, Troina, Italy

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
BCBradley P Coe
Bradley P Coe
KWKali Witherspoon
Kali Witherspoon
JRJill A Rosenfeld
Jill A Rosenfeld
BBBregje W M van Bon
Bregje W M van Bon
ASAnneke T Vulto-Van Silfhout
Anneke T Vulto-Van Silfhout
FMF. Kumara Eugene Mastrorosa
F. Kumara Eugene Mastrorosa
Evan Eichler and colleagues report an expanded copy number variation (CNV) morbidity map of developmental delay, with additional resequencing of candidate genes in regions implicated by large CNVs. They identify several new disease-associated CNVs and show how their combined approach facilitates discovery of new developmental syndromes and disease genes. Copy number variants (CNVs) are associated with many neurocognitive disorders; however, these events are typically large, and the underlying causative genes are unclear. We created an expanded CNV morbidity map from 29,085 children with developmental delay in comparison to 19,584 healthy controls, identifying 70 significant CNVs. We resequenced 26 candidate genes in 4,716 additional cases with developmental delay or autism and 2,193 controls. An integrated analysis of CNV and single-nucleotide variant (SNV) data pinpointed 10 genes enriched for putative loss of function. Follow-up of a subset of affected individuals identified new clinical subtypes of pediatric disease and the genes responsible for disease-associated CNVs. These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features. This combined CNV and SNV approach facilitates the rapid discovery of new syndromes and genes involved in neuropsychiatric disease despite extensive genetic heterogeneity.

6 July 2004 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
ARAntonino Romano
Antonino Romano
RGRosa-Maria Guéant-Rodriguez
Rosa-Maria Guéant-Rodriguez
MVMarinella Viola
Marinella Viola
RPRosa Pettinato
Rosa Pettinato
JGJean-Louis Guéant
Jean-Louis Guéant
In patients with documented IgE-mediated hypersensitivity to penicillins, data on sensitization to cephalosporins vary. Administering cephalosporins to such patients is often deferred because of the risk for cross-reactivity. To assess the cross-reactivity with cephalosporins and its potential determinants in patients with documented penicillin allergy. Prospective study in patients without clinical indications for cephalosporin treatment. Italy. 128 consecutive patients who sustained anaphylactic shock (n = 81) or urticaria (n = 47) and had positive results on skin tests for at least 1 of the penicillin reagents tested. All patients were skin tested with cephalothin, cefamandole, cefuroxime, ceftazidime, ceftriaxone, and cefotaxime. Patients with negative results for the last 4 cephalosporins were challenged with cefuroxime axetil and ceftriaxone. 14 patients (10.9% [95% CI, 6.1% to 17.7%]) had positive results on skin tests for cephalosporins, mostly for cephalothin or cefamandole. Skin test results for the minor determinant mixture were positive in 10 of 14 patients (71.4%) with cross-reactivity and 44 of 114 patients (38.6%) without cross-reactivity (odds ratio, 3.90 [CI, 1.17 to 13.40]; P = 0.0189). All 101 patients with negative results on skin tests for cefuroxime, ceftazidime, ceftriaxone, and cefotaxime tolerated cefuroxime axetil and ceftriaxone (tolerability rate, 100% [CI, 96.4% to 100%]). Challenges were not followed by full therapeutic courses. Twenty-two patients declined challenges; positive responses in those patients would have decreased the tolerability rate to 82.1% (CI, 74.2% to 88.4%). These data confirm the advisability of avoiding cephalosporin treatment in patients with positive results on skin tests for penicillin. In patients who especially require cephalosporin treatment, we recommend skin tests with cephalosporins before assessing the tolerability of the cephalosporin with a graded challenge.

29 June 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ARAntonino Romano
Antonino Romano
MVMarinella Viola
Marinella Viola
RGRosa-Maria Guéant-Rodriguez
Rosa-Maria Guéant-Rodriguez
FGFrancesco Gaeta
Francesco Gaeta
RPRosa Pettinato
Rosa Pettinato
JGJean-Louis Guéant
Jean-Louis Guéant
It is considered potentially harmful to administer imipenem–cilastatin to patients with IgE-mediated hypersensitivity to penicillins1 because of a 47.4 percent rate of cross-reactivity (9 of 19 subjects) found in a single study2 on the basis of positive skin tests involving imipenem reagents.

1 October 2002 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
ARAntonino Romano
Antonino Romano
MVMarinella Viola
Marinella Viola
CMChiara Mondino
Chiara Mondino
RPRosa Pettinato
Rosa Pettinato
MFMarina Di Fonso
Marina Di Fonso
PMPaolo Montuschi
Paolo Montuschi
Background: Maculopapular and urticarial rashes are nonimmediate manifestations common during penicillin treatment; the former often represent cell-mediated hypersensitivity. Our objectives were to assess the incidence of allergy in adults reporting nonimmediate manifestations during penicillin therapy and to evaluate the diagnostic potential of patch tests, delayed-reading skin tests and challenges in such cases. Methods: We used prick and intradermal tests as well as patch tests with penicillin determinants, ampicillin, amoxicillin and any other suspect penicillins. We also performed challenges with the suspect antibiotics. Results: Such antibiotics were aminopenicillins in 93.1% of 259 patients, most of whom had suffered from maculopapular rashes followed by piperacillin (4.2%). Three subjects displayed immediate skin test positivity. Ninety-four subjects showed patch test and delayed intradermal test positivity to the culprit penicillin (90 to aminopenicillins and 4 to piperacillin) and were considered as having had delayed hypersensitivity reactions. Five of the 8 subjects who displayed delayed intradermal test positivity and patch test negativity to the suspect penicillin underwent challenges, 2 reacted positively to the responsible aminopenicillin. Among the remaining 154 with negative results in allergologic tests, 125 agreed to undergo challenges; only 3 reacted. In all, 98 patients – 93 of whom had experienced maculopapular rashes – displayed delayed hypersensitivity (94 to aminopenicillins and 4 to piperacillin). Conclusions: Both patch and intradermal tests are useful in evaluating nonimmediate reactions to penicillins, particularly maculopapular rashes. Patch test and delayed intradermal positivity together indicate delayed hypersensitivity. Intradermal testing appears to be slightly more sensitive than patch testing.

10 June 2011 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
Giuseppe MarangiGiuseppe Marangi
Giuseppe Marangi
SRStefania Ricciardi
Stefania Ricciardi
DODaniela Orteschi
Daniela Orteschi
Serena LattanteSerena Lattante
Serena Lattante
MMMarina Murdolo
Marina Murdolo
MZMarcella Zollino
Marcella Zollino

1 July 2002 in Dermatology
Verified
Journal Article
Closed access
PDF file
CSCarmelo Schepis
Carmelo Schepis
CBConcetta Barone
Concetta Barone
MSMaddalena Siragusa
Maddalena Siragusa
RPRosa Pettinato
Rosa Pettinato
Corrado RomanoCorrado Romano
Corrado Romano
Background: Only three not concordant surveys have been published on skin conditions associated with Down syndrome. Objective: A sample ranging from infancy to adulthood, using acknowledged criteria for diagnosis, may highlight the skin involvement in Down syndrome. Methods: We report the skin conditions observed in 203 people with Down syndrome, separated according to five different age ranges. We have set up two main groups of skin features: the phenotype and the dermatological diseases. Results: The single palmar crease and xerosis are strongly represented within the phenotype. Among the dermatological diseases, folliculitis and syringomas have been observed mainly in adolescence and adulthood. Atopic dermatitis has been recognized in 10 subjects. Alopecia areata and milia-like idiopathic calcinosis cutis appeared in 6 subjects. Conclusion: People with Down syndrome suffer from peculiar dermatoses (syringomas, milia-like calcinosis, elastosis perforans serpiginosa). Other conditions (folliculitis, alopecia areata) are frequently observed.